|
|
 |
|
Viewing report
|
|
|
|
Acute Coronary Syndrome - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 752
This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Inverness Medical Innovations, Inc., Merck & Co., Inc., Medicure Inc., Novartis AG, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Schering-Plough Corp., Siemens Healthcare Diagnostics, Inc., Takeda Pharmaceutical Company Limited, and The Medicines Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Acute Coronary Syndrome Global Clinical Trials Review, H2, 2011
The Executive’s Guide to the World’s Leading Pharmaceutical Companies 2007
Prescription Drugs - Global Strategic Business Report
Cardiovascular Drugs - Global Strategic Business Report
Getting Maximum Benefit from Combination Products
Value-Added Pharma: How to Accomplish the Impossible
Top 20 Company Pipelines 2010
Partnering Agreements with BigPharma
Pharmaceuticals - Global Outlook
Anti-Hypertensive Drugs - Global Strategic Business Report
|
|
|
|
